Am J Transplant, Volume 5, Suppl 3 Archives - Page 159 of 170 - ATC Abstracts

2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
X. Zervos,¹ D. Beltran,² B. Ismail,¹ M. Watson,¹ D. Sears,¹ A. Tzakis.¹
¹Liver Transplant, Cleveland Clinic Florida, Weston, FL; ²Pharmacy, Cleveland Clinic Florida, Weston, FL.
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…
2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
M. Gastaca, A. Valdivieso, J. Bustamante, P. Ruiz, J. Fernandez, A. Ventoso, M. Testillano, I. Palomares, P. Salvador, M. Prieto, A. Matarranz, M. Suarez, J. Ortiz de Urbina.
Liver Transplantation Unit, Cruces University Hospital. University of the Basque Country, Bilbao, Vizcaya, Spain.
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…
2015 American Transplant Congress
Outcomes of Solid Organ Transplantation in a National Private Health Plan: Comparison to SRTR Reports
F. Irwin,¹ C. Wu,¹ W. Bannister,² M. Schnitzler,¹ A. Bonagura.¹
¹Optum, Minneapolis; ²Saint Louis University, St. Louis.
The majority of transplant recipients have private health plans. However, there have been few reports using private health plan data describing the outcomes of this…
2015 American Transplant Congress
Dual PI3K-mTOR Inhibition on Human T Cell Activation, Proliferation, and Differentiation: The First Step in the Development of New Immunosuppressants
V. Vilchez,¹ A. Castellanos,¹ D. Butterfield,³ M. Mitov,³ C. Hoopes,¹ F. Marti,² R. Gedaly.¹
¹Department of Surgery - Transplant Section, University of Kentucky, Lexington, KY; ²Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY; ³Free Radical Biology in Cancer Shared Resource Facility, University of Kentucky, Lexington, KY.
Background: Regulatory T lymphocytes (Tregs) contribute to transplant tolerance. We have demonstrated that the inhibition of PI3K-mTOR pathway has a major role in the differentiation…
2015 American Transplant Congress
ECDI Fixed Donor Splenocytes Combined With α-1 Antitrypsin Induce Immune Tolerance in Mice Cardiac Transplantation Model
G. Chen,¹ X. Lai,¹ J. Qiu,¹ L. Qiu,² X. Mai,² L. Chen.¹
¹Organ Transplant Center, The first affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; ²Zhongshan Medical School, Sun Yat-sen University, Guangzhou, Guangdong, China.
Our previous study have shown that infusions of donor splenocytes fixed with 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (ECDI-SPs) could prolong allografts survival in mice cardiac transplantation model. However, proinflammatory…
2015 American Transplant Congress
The Use of Inhaled Tobramycin in Pediatric Transplant Patients Without Cystic Fibrosis
C. Pfeifer,¹ M. Keck.²
¹Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY; ²Department of Pharmaceutical and Nutrition Care, Nebraska Medicine, Omaha, NE.
Purpose:To evaluate dosing strategies used and systemic levels achieved of inhaled tobramycin in pediatric patients without cystic fibrosis (CF)Methods:A retrospective single-center chart review was performed…
2015 American Transplant Congress
Early Antibody Mediated Rejection in HLA Antibody Incompatible Kidney Transplantation – A Treatable Condition Without Heavy Induction Immunosuppression
S. Daga,^1,2 N. Krishnan,¹ D. Lowe,³ F. Lam,¹ C. Imray,^1,2 H. Kashi,¹ L. Tan,¹ D. Briggs,³ R. Higgins.^1,2
¹Renal Department, University Hospital, Coventry, United Kingdom; ²Warwick Medical School, University of Warwick, Coventry, United Kingdom; ³H&I Department, NHSBT, Birmingham, United Kingdom.
Transplantation across preformed donor specific HLA antibodies (DSA) not only carries a risk of early acute antibody mediated rejection (AMR) and graft loss, but also…
2015 American Transplant Congress
Prevalence, Risk Factors, and Clinical Management of Chronic Renal Dysfunction in Heart Transplant Recipients
K. Xhima, O. Famure, Y. Li, J. Kim.
Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Background: Chronic kidney disease (CKD) is a frequent complication after heart transplantation. The magnitude of post-transplant CKD makes it necessary to characterize patients at increased…
2015 American Transplant Congress
Role of Universal Decolonization After Kidney Transplant: A Pilot Study
D. Lee,¹ G. Malat,² N. Law,¹ A. Sharma,¹ T. Bias,¹ K. Ranganna,¹ A. Doyle.¹
¹Department of Medicine, Drexel University, College of Medicine, Philadelphia, PA; ²Department of Surgery, Drexel University, College of Medicine, Philadelphia, PA.
IntroductionInfection is a common cause of morbidity and mortality after kidney transplantation. Despite careful pre-transplantation screening of donors and recipients, vaccination, prophylaxis, and antimicrobial use,…
2015 American Transplant Congress
Ex Vivo Stem Cell-Mediated Regeneration of Ischemically Damaged Renal Allografts
L. Brasile, N. Henry, A. Meyer, B. Stubenitsky.
BREONICS, Inc., Watervliet, NY.
This project attempted to accelerate repair of ischemically damaged human kidney allografts using Exsanguinous Metabolic Support (EMS) technology that is warm (32C) and acellular. While…